Nvidia shares key technical levels

Nvidia has undoubtedly been the world’s most closely watched stock this week.

Earnings released on Wednesday produced a disappointing reaction in the stock, but the results themselves were not a disappointment as they confirmed momentum in demand for chips was intact.

Expectations were high going into Nvidia’s earnings update this week, and anything less than a blowout to the upside was going to weigh on shares.

As the stock settles into a trading range, analysts at XS.com have provided technical commentary on the key levels for NVDA shares in the coming trading sessions:

“The better-than-expected report is likely to lead to price fluctuations with an upward bias, but the stock’s decline and breach of the 50-day moving average at $117.70 could result in further weakness,” said Rania Gule Senior Market Analyst at XS.com.

“Looking ahead to the medium and long term, the markets should respect four key technical price levels that may play a role if Nvidia’s shares continue to decline following yesterday’s strong earnings.

Image

“The first support level is at $116. This area may provide initial support near the trendline connecting the May peak and the counter-trend price surge that occurred in early August. A move below this level could push the stock down to the $107 region, a key demand and reversal area on the daily chart between May and August.

“Further decline may lead to a retest of the crucial $99 level, where Nvidia shares are likely to encounter significant support near the March peaks, with the first of these peaks representing the previous all-time high for the stock.

“Lastly, it’s essential to watch the $91 zone, which is a lower price target for the descending column pattern from July to August, identified from the highest point of the recent price channel formation. Should such a move occur, it would confirm a descending channel pattern in the stock and could potentially lead to a retest of this month’s low at $90.70 in the medium term.”

Filtronic receives another SpaceX order

Filtronic plc, a leading designer and manufacturer of products for aerospace, defence, space, and telecoms infrastructure markets, has announced a new production order from SpaceX valued at $8.4 million.

This order continues the demand for Filtronic’s E-band solid state power amplifier (SSPA) modules, crucial components in SpaceX’s Starlink satellite constellation.

The irrevocable order is set to be fulfilled in the calendar year 2025, prompting Filtronic to upgrade trading projections to be ahead of current market expectations for FY2025.

This latest contract win falls under the Strategic Partnership agreement signed in April 2024.

“We are delighted to receive another production order from our partner, SpaceX, as we continue to support the deployment of the Starlink constellation with E-band technology,” said Nat Edington, Chief Executive Officer of Filtronic.

The order has triggered SpaceX’s vesting of an additional 2,171,211 share warrants as part of the long-term partnership established between SpaceX and Filtronic earlier this year.

This brings the total number of vested warrants under the first tranche to 10,856,055, reaching the maximum 5% of the company’s share capital as stipulated in the agreement. With this milestone, Filtronic confirms that future E-band SSPA orders from SpaceX will no longer result in further warrant vestings under this tranche.

ECR Minerals eyes helium bandwagon

ECR Minerals looks set to be the latest natural resources junior to add a helium project to its investments.

Citing recent excitement in the share prices of companies that have pivoted towards helium, ECR wants a piece of the action and announced the expansion of its strategy to include US helium projects. 

A number of UK-listed shares that have hit a dead end with existing operations have shifted to helium to revive the company’s prospects.

ECR Mineral’s Chairman and Managing Director, Nick Tulloch has experience reinventing cannabis company Voyager Life as a helium play.

Voyager’s shares collapsed early in 2024 following a failed merger with another cannabis firm, and the company emerged as a helium producer. 

Helium has a wide range of medical and industrial applications and is important for space travel.

ECR Minerals says it sees value in selling and distributing helium in the US and will target only assets in production or with the potential for near-term production.

Comments accompanying today’s announcement highlight the difficulties of extracting helium, and the company made it clear it didn’t want to get involved in helium exploration.

“Although it is often tempting to think that the important part of developing a natural resources play is to find the resource, in fact we consider that it is production and sales that really define a company,” said Nick Tulloch, Chairman of ECR Minerals.

“There are many substantial resource deposits globally that are simply not economic – or possible – to extract and sell. This is particularly the case with helium. Despite its high value, it is not a straightforward element to process or transport.”

“Therefore, as we examine this possible expansion of ECR, it is critical that we source assets that are capable of near term production, and therefore sales, of helium and access to nearby infrastructure, both gathering lines and a processing plant, is a must.”

Touching on the funding of ECR Mineral’s expansion into helium, the company said it wouldn’t conduct a placing at a discount to the current share price.

FTSE 100 shakes off Nvidia wobble, banks rebound

The FTSE 100 has shaken off any concerns about disappointing Nvidia earnings and pushed higher on Thursday with banking and consumer stocks among the top risers.

Although Nvidia shares fell after the company announced results last night, the drop can be attributed to profit-taking rather than any major concerns with the numbers. There certainly wasn’t anything in the numbers to suggest the AI theme was coming to an end or that there was any slowdown in momentum.

“The FTSE 100 ticked higher despite a technology-led sell-off in the US overnight and a negative after-hours reaction to Nvidia’s results – the lack of tech stocks in the UK index proving a rare boon on Thursday morning,” said AJ Bell investment director Russ Mould.

“Consumer-facing names were getting some love from the market along with resources stocks on a quiet day in London for corporate news.”

We mentioned yesterday that the FTSE 100 has shown remarkable resilience throughout August’s volatility. Although there are many occasions that investors wish they had a greater weighting to US tech than FTSE 100, today’s 0.3% gains for the FTSE 100 is a reminder of the defensive nature of the index and its ability to preserve value when other markets are under the cosh.

Banks rebound

UK banks rebounded a day after a comment in an FT article suggested the Labour government could be eyeing up banking profits in their upcoming tax raid budget.

“UK banking stocks came under some pressure yesterday after reports suggested the new government may be looking at additional taxes on the sector,” said Matt Britzman, senior equity analyst, Hargreaves Lansdown.

“There’s precedent here, the sector already suffers from elevated taxes in the form of the bank levy and corporation tax surcharge. Details are thin on the ground but given any tax would likely be UK focused, this would impact domestic players like Lloyds and NatWest more so than those with a global presence.”

Any concerns about the impact of additional taxes were short-lived, as the government itself is yet to signal that it was planning additional taxes on banks. Lloyds shares rose 1%, and Barclays ticked 1.6% higher. After a strong rally in recent weeks, things could become very interesting for banking stocks should Rachel Reeves drop in any hints to back up yesterday’s jitters.

Diageo was the top faller after one of its peers posted soggy results. Diageo has released a series of disappointing updates, and it appears that peers are experiencing their problems, suggesting that its woes may persist.

AIM movers: Quiz revenues decline and ex-dividends

0

Kazera Global (LON: KZG) says that the on-site inspection of the Whale Head heavy minerals sands project in South Africa by the consultant for the National Nuclear Regulator has been completed. This means that there is consent for mining and processing. The share price is 18.4% higher at 1.125p.

Workplace software provider essensys (LON: ESYS) has completed its transition to a SaaS-based model and its trading is better than expected. Full year revenues were £24m and loss was lower than forecast. There is cash of £3.1m. There should be a further fall in loss this year and a modest decline in cash. The share price is 13.1% ahead at 34.5p.

Seed Innovations (LON: SEED) finance director Lance de Jersey has acquired one million shares at 1.45p each. That takes his stake to 1.4 million shares.  The share price improved 7.14% to 1.5p.

Healthcare services provider Totally (LON: TLY) has won £1.25m of new business. This includes a £1m insourcing award for ophthalmology outpatient clinics in Galway and Sligo via Saolta Group. There is also a £250,000 contract for physiotherapy services in England. There are also two contract extensions worth £2.75m. The share price rose 5.41% to 9.75p.

FALLERS

Retailer Quiz (LON: QUIZ) reported a 11% decline in revenues to £82m in the year to March 2024. There was a swing from a pre-tax profit of £2.3m to a loss of £6.7m after exceptional costs of £1.5m. Sheraz Ramzan was appointed chief executive at the end of the period. He is targeting the core customer based and updating the brand. He is also improving service. Talks are ongoing with founder Tarak Ramzan for the provision of a £1m loan. Revenues in the first four months of the current year are 11% lower at £27.3m. Trading remains difficult. The share price declined 14.4% to 4.34p.

Specialist IFA and expert witness services Frenkel Topping (LON: FEN) expects a decline in profit in 2024 even though revenues should be higher. This is due to delays in winning business by the legal services business Partners in Costs after adding additional staff. Cavendish forecasts a fall in pre-tax profit from £7.2m to £6.8m this year. The share price slipped 5.1% to 46.5p.  

Zenova Group (LON: ZED) has received an inaugural order for 1,500 Zenova FX500 extinguishers with UK fire and safety distributor O. Heap & Son. This small fire extinguisher fits a gap in the distributor’s product range. The share price fell 4.17% to 1.15p.

Security systems supplier Synectics (LON: SNX) says that chief executive Paul Webb has died. He has been in the position for nine years. Amanda Larnder will become interim chief executive. The share price dipped 3.94% to 195p.

Ex-dividends

Brickability (LON: BRCK) is paying a final dividend of 2.28p/share and the share price declined 3p to 66.5p.

Knights Group Holdings (LON: KGH) is paying a final dividend of 2.79p/share and the share price is 0.25p higher at 130p.

Northern Bear (LON: NTBR) is paying an interim dividend of 2p/share and the share price fell 1.5p to 59.5p.

PetroTal Corp (LON: PTAL) is paying a dividend of 1.5 cents/share and the share price is 0.25p lower at 40p.

Quartix Holdings (LON: QTX) is paying an interim dividend of 1.5p/share and the share price is unchanged at 185p.

Team Internet Group (LON: TIG) is paying an interim dividend of 1p/share and the share price slipped 2.7p to 132.7p.

The opportunity in e-waste recycling and the circular economy with Majestic Corporation

The UK Investor Magazine was delighted to welcome Peter Lai, CEO of Majestic Corporation, to the podcast for a deep dive into the emerging leader in sustainable circular economy solutions.

Aquis-listed Majestic Corporation specialises in recycling and recovering precious and base metals from everyday materials that societies routinely discard. This includes electronics, catalytic converters, solar and battery materials.

CEO Peter Lai outlines the benefits of recycling metals as opposed to mining, both from an environmental perspective, and from an economic perspective.

Majestic Corporation has recently posted strong results for FY2023. Highlights include a 25% increase in revenue to US$29.4m and a 149% surge in profit before tax.

Peter details Majestic’s growth strategy and what excites him the most about future developments for the company.

Lloyds shares: investors must contend with further pressure amid tax raid speculation

Lloyds shares were higher on Thursday after falling in the prior session, as investors considered the merits of holding the UK bank’s shares near 52-week highs.

In an article recently published by the UK Investor Magazine, we explained that the end of rising interest rates made the UK banking sector less attractive, and key profitability metrics are set to come under pressure in the coming periods.

Lower interest rates will ultimately result in lower net interest margins and lower income for banks unless they experience a material increase in lending activity, which doesn’t seem likely.

However, Lloyds investors now have a fresh threat to the share price—the new Labour government. 

Keir Starmer has made it clear he and Rachel Reeves will announce plans for a tax raid in the upcoming budget, and banks are in the firing line. 

Along with speculation around changes to inheritance tax and capital gains tax, Labour are thought to be eyeing up banking profits to boost the public coffers.

As Dan Coatsworth, an investment analyst at AJ Bell, explains, banks are easy targets for the treasury, as they can generate billions in extra tax receipts with little public backlash.

“Keir Starmer and Rachel Reeves have made it perfectly clear they will leave no stone unturned in the search to find ways to boost public finances. That also means being creative with where they impose tax and it seems the banking sector could be in their sights,” Dan Coatsworth said.

“It’s about as easy a target as you can get. No-one is going to shed any tears if the banks are forced to hand over more of their profits.

“Banks have made big money from higher interest rates, profiting when the rest of the country has struggled through a cost-of-living crisis. If the oil and gas industry can be slapped with a windfall tax as a result of a spike in energy prices, so can the banks as a result of higher rates.”

The double whammy of falling interest rates impacting the top line and additional taxes eroding what’s left on the bottom line must be carefully considered by Lloyds investors.

Tekcapital’s Innovative Eyewear secures Target.com listing

In a significant move to broaden its market presence, Tekcapital portfolio company Innovative Eyewear (NASDAQ:LUCY) has announced the availability of its Lucyd Lyte frames on Target.com.

Tekcapital has made a number of announcements regarding developments for Innovative Eyewear in 2024; today’s may just be the most important one, both in terms of potential revenue generation and the delivery on Innovative Eyewear’s strategy to focus distribution through retail outlets.

The partnership with Target.com brings Lucyd ChatGPT-enabled smart eyewear to one of the largest retail platforms in the United States. Target Corporation, with its vast network of nearly 2,000 stores across the country and a robust online presence, serves millions of US customers daily.

By securing a place on Target.com, Innovative Eyewear gains access to a massive customer base, potentially exposing its smart eyewear products to millions of new consumers nationwide.

“Target is a long-time favourite retailer of mine, as well as millions of loyal customers in the US,” said Harrison Gross, CEO of Innovative Eyewear

“Their focus on product quality, style and accessibility makes Target.com an ideal channel partner for our smart frames. We look forward to upgrading Target guests’ eyewear.”

Innovative Eyewear, which develops and retails smart eyewear under well-known brands such as Lucyd®, Nautica®, Eddie Bauer®, and very shortly, Reebok®, has achieved a step-change in revenue generation this year.

The company has outlined a growth strategy to focus on retail distribution in order to reach millions of consumers. Securing a listing on Target.com does just that.

Nvidia shares sink despite earnings beating estimates

Nvidia shares were down in the US premarket after the company reported eagerly anticipated quarterly earnings overnight. 

In many respects, Nvidia was set up to fail going into results. Simply beating analyst earnings expectations is not enough for Nvidia. Their importance to the AI trade means markets want to see the chip maker smash estimates by many billions, even if they doubled revenue compared to a year ago. 

“The most important earnings release in the entire history of the world – at least if you believe the hype beforehand – saw NVDA deliver both top- and bottom-line beats, coupled with better-than-expected third quarter guidance, as well as promising news on the delivery of the new ‘Blackwell’ chip,” said Michael Brown Senior Research Strategist at Pepperstone.

“While those at Nvidia earnings watch parties (bubble sign, perhaps!?) would’ve been pleased with the earnings slate, market participants appeared rather disappointed, with NVDA ending the after-hours session 7% softer, having failed to meet what, in hindsight, was an impossibly high bar that investors had set.”

The sharp ascent in the share price over the past two years means the investors are ultra-sensitive to any suggestion of a slowdown in momentum.

Nvidia trades at an earnings multiple considered to be rich compared to historical averages. With such a high valuation, earnings have to run higher faster just for Nvidia shares to stand still.

That said, there weren’t any major concerns with last night’s report and today’s drop is likely a round a profit taking after a meteoric rise in the stock.

“Revenue jumped 122% year-over-year to $30.04 billion, and its data centre revenue grew 154% to $26.3 billion, both smashing through estimates. Nvidia also announced an additional $50 billion buyback program, signalling its confidence in what’s ahead after ending the quarter with a massive cash balance of $34.8 billion,” Josh Gilbert, Market Analyst at investment platform eToro summarised.

As well as recent finanical performance, Nvidia provided insight into the rollout of its new Blackwell chips, saying it will sell billions of dollars in the coming periods. In addition, investors would have been encouraged to hear the Nvidia CEO in his traditionally bullish mood on last night’s earnings call, highlighting robust demand from the world’s largest tech companies.   

“The market may be disappointed not to see a bigger beat on its outlook given what is now almost unattainable expectations, but the bottom line here is that the long-term story remains intact, demand remains huge and the Juggernaut that is Nvidia rolls on,“ Gilbert said.

hVIVO – Foundations Laid For Strong Performance In The Months And Years Ahead, Institutions Building Up Stakes Ahead Of Interims 

Next Monday, 2nd September, will see hVIVO (LON:HVO) cancelling dealing of its shares on the Euronext Growth Market. 

This is quite a sensible move by the £200m capitalised contract research group, it will consolidate trading of its stock into its primary AIM listing, especially as the company’s main operations, the majority of its employees, as well as most of its investor base are all in the UK. 

Just imagine all of the associated costs and duplication of activities involved with maintaining its dual listings, a big chunk of which will now be removed. 

The Business  

Based in the UK, the company is engaged in pioneering a technology platform of human disease models to accelerate drug discovery and in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. 

It considers that it is the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials.  

It provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. 

Its fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products.  

The company has world-class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing.  

The group also offers additional clinical field trial services such as patient recruitment and clinical trial site services by recruiting volunteers / patients for its studies by via its FluCamp volunteer screening facilities in London and Manchester. 

hVIVO runs challenge trials in London – its new state-of-the-art facilities in Canary Wharf opened earlier this year and is the world’s largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit.  

Recent Trading Update 

In mid-July the company reported that it expects to show first half revenues of £35.6m representing 30.6% revenue growth on H1 2023.  

That increase was driven by exceptional operational delivery across the group, particularly with a record number of volunteer inoculations across multiple studies and a variety of challenge models running simultaneously.   

CEO Mo Khan stated that: 

“The results of H1 2024 reflect the hard work, flexibility and commitment of the team.  

During a period of significant activity including the build-out and move to a new facility, we have not only materially increased our revenue but also further improved our margins.  

The concurrent running of three different facilities helped to boost our revenues for H1 2024, creating an expected H1 2024 weighting. 

We have full visibility over our expected 2024 revenues and continue to deliver on our sustainable growth strategy.  

The orderbook remains strong in spite of record revenue delivery in H1 2024.  

The recent Omicron characterisation study contract and the award of our largest field study to date are two key sales highlights for H1 2024. 

In addition, the current sales pipeline includes several advanced stage opportunities that we expect to convert in the coming months.   

The outlook for hVIVO is positive as we welcomed our first volunteers into our new facility at Canary Wharf – the world’s largest human challenge trial unit.  

I believe we have laid the foundations for strong performance in the months and years ahead.” 

Analyst View 

At Cavendish Capital Markets, its analysts Stuart Harris and Chris Donnellan approve of the Euronext quote being cancelled, appreciating the cost savings. 

Ahead of the company declaring its results for the six months to the end of June, due on Tuesday 10th September, the analysts are giving a 42p Price Objective on the group’s shares. 

The are estimating that the current year to end December will show revenues up to £62.0m (£56.0m), while its adjusted pre-tax profits could rise to £12.2m (£11.9m), lifting its earnings up to 1.4p (1.3p) and paying a 0.2p per share dividend. 

Jumping forward into 2025 they foresee £67.4m sales, £12.9m profits, 1.6p earnings and maintaining the 0.2p dividend. 

In My View 

I like the way that Mo Khan and his team have obviously impressed a number of the City investing institutions. 

Fund manager Neil Hermon, the Janus Henderson fund manager, has recently added a wad of the group’s shares into the Henderson Smaller Companies Trust, he considers that Hvivo offered a relatively cheap and effective way to undertake accelerated drug development. 

“The barriers to entry in this niche industry are high as the proprietary datasets about viral loads can only be built through experience.  

The business is focussed on both organic growth, through the development of ancillary services, and inorganic growth. 

Management has set ambitious medium-term revenue and margin targets and our investment gives us exposure to structural growth in this niche market.” 

Earlier this year I was interested to note the gradual way that JP Morgan Asset Management built up its 7.04% stake in the group. 

Then at the start of July, Octopus Investments bought another 1m shares, to add to its holding of 20,175,000 shares, taking it through the declarable 3% level, up to 3.10%. 

11 days later it was up to 30,054,020 shares, representing 4.42% of the equity. 

After another 7 days it was up to 51,804,020 shares (7.61%). 

And it continued with another purchase on Monday 5th August, pushing it up to 54,438,725 shares, a neat 8.0% holding. 

In my view patient investors should be adding HVO shares, now 29p, to their growth portfolios.